Archives for: May 5th, 2017

CorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update

Written by Josh Drumm, Ph.D. on May 5, 2017

Conference Call and Webcast to be held Wednesday, May 10,…

CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter’s Exercise in Full of Over-Allotment Option

Written by Josh Drumm, Ph.D. on May 4, 2017

Bedminster, NJ – May 3, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million

Written by Josh Drumm, Ph.D. on April 28, 2017

Bedminster, NJ – April 28, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Announces $10 Million Underwritten Public Offering

Written by Josh Drumm, Ph.D. on April 27, 2017

Bedminster, NJ – April 27, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports Update on Neutrolin® Phase 3 LOCK-IT 100 Clinical Trial

Written by Josh Drumm, Ph.D. on April 20, 2017

Bedminster, NJ – April 20, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin®

Written by Josh Drumm, Ph.D. on April 12, 2017

Bedminster, NJ – April 12th, 2017 – CorMedix Inc. (NYSE…

CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Written by Josh Drumm, Ph.D. on March 17, 2017

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time…